Medios focuses on specialty pharma logistics, shares trade steadily on Xetra
Published on 06/25/2026 at 20:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-25, 20:55.
Medios (DE000A1MMCC8) positions itself as a specialist for individualized pharmaceutical care in Germany. The company focuses on compounding, trading and logistics for specialty pharmaceuticals, serving pharmacies and clinics via its listing on Xetra as part of the healthcare distribution segment.
How Medios runs its operations
Medios centers its business on three pillars that recur in its reporting: specialty pharmaceutical trading, patient-specific compounding and related logistics services for pharmacies and clinics in Germany, particularly for complex therapies such as oncology and autoimmune diseases. Medios investor relations overview
The company operates an integrated supply chain from procurement to delivery of high-value therapies, which requires strict quality and temperature control standards. This set-up aligns Medios with peers in the specialty distribution niche such as Phoenix Group or McKesson’s European activities, though Medios focuses on the German-speaking market.
Position in the healthcare distribution sector
Within the broader European healthcare distribution landscape, Medios competes with large wholesalers and specialized providers that handle biologics and other high-cost medicines. These markets are shaped by pricing regulation, rebate contracts and strict GDP/GMP compliance requirements across the EU. Handelsblatt analysis of European pharma wholesalers
Analyst and market commentary on European specialty distribution frequently highlight stable but low-margin trading, with value creation coming from services such as compounding, cold-chain logistics and clinical support. Medios’ focus on individualized therapies places it in this service-oriented segment of the value chain.
All news and data on the Medios shares
Follow further regulatory filings, corporate releases and price data on Medios to track developments in the specialty pharma distribution business.
The product behind the stock
One concrete pillar in the Medios portfolio is patient-individual compounding of oncology and autoimmune therapies for partner pharmacies. These personalized preparations are produced in certified clean-room facilities under strict GMP standards and supplied via controlled logistics channels to treating physicians and clinics.
Where the stock trades today
The Medios shares (DE000A1MMCC8) most recently traded on Xetra with pricing in euros; the latest verifiable real-time quote and exact timestamp are provided by the German exchange data services.
Key data on the Medios shares
- Company: Medios AG
- ISIN: DE000A1MMCC8
- WKN: A1MMCC
- Ticker: ILM
- Trading venue: Xetra
- Price (as of latest exchange data): data in euros via Xetra
- Market cap: based on Xetra free-float valuation in euros (latest available)
- Sector / industry: Healthcare, pharmaceutical distribution and services
- Index membership: listed in the German small and mid cap universe, outside the DAX blue-chip segment
- Next earnings date: not officially scheduled
This text does not contain investment advice or recommendations to buy or sell securities. All information is based on publicly available sources and is provided without any guarantee of completeness or accuracy.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
